Analyzing Agios Pharmaceuticals (NASDAQ:AGIO) & Briacell Therap (NASDAQ:BCTX)

Agios Pharmaceuticals (NASDAQ:AGIO) and Briacell Therap (NASDAQ:BCTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Agios Pharmaceuticals and Briacell Therap, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1	4	5	0	2.40
Briacell Therap	1	0	0	0	1.00

Agios Pharmaceuticals currently has a consensus target price of $41.25, indicating a potential upside of 22.91%. Given Agios Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than Briacell Therap.

Profitability

This table compares Agios Pharmaceuticals and Briacell Therap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Briacell Therap	N/A	-153.53%	-129.26%

Valuation and Earnings

This table compares Agios Pharmaceuticals and Briacell Therap”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03 million	37.08	-$412.78 million	($7.01)	-4.79
Briacell Therap	N/A	N/A	-$26.31 million	($7.92)	-0.43

Briacell Therap has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agios Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

15.4% of Briacell Therap shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Agios Pharmaceuticals beats Briacell Therap on 8 of the 13 factors compared between the two stocks.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.